KWS 2982772

Lub npe tshuaj:

(S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b]-[1,4]oxazepin-3-yl)-4H-1,2, 4-triazole-3-carboxamide

SMILES Code:

O=C(C1=NN=C(CC2=CC=CC=C2)N1)N[C@@H]3C(N(C)C4=CC=CC=C4OC3)=O

InChi Code:

InChI = 1S/C20H19N5O3/c1-25-15-9-5-6-10-16(15)28-12-14(20(25)27)21-19(26)18-22-17(2) 3-24-18) 11-13-7-3-2-4-8-13/h2-10,14H,11-12H2,1H3,(H,21,26)(H,22,23,24) /t14-/m0/s1

InChi Key:

LYPAFUINURXJSG-AWEZNQCLSA-N

Lo lus tseem ceeb:

GSK-2982772, GSK 2982772, TSW 2982772, 1622848-92-3

Solubility:Soluble hauv DMSO

Cia:0 - 4 ° C rau lub sijhawm luv (hnub mus rau lub lis piam), lossis -20 ° C rau lub sijhawm ntev (hli).

Nqe lus piav qhia:

GSK2982772 yog ib qho muaj zog thiab xaiv receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate for the Treatment of Inflammatory Diseases. GSK2982772 yog, tam sim no nyob rau theem 2a kev tshawb fawb soj ntsuam rau psoriasis, mob caj dab rheumatoid, thiab mob plab ulcerative. GSK2982772 muaj zog khi rau RIP1 nrog cov kinase tshwj xeeb thiab muaj kev ua haujlwm zoo hauv kev thaiv ntau TNF-nyob ntawm cov lus teb ntawm tes. RIP1 tau tshwm sim los ua ib qho tseem ceeb ntawm cov dej ntws kinase uas tau pom tias tswj kev mob los ntawm ob qho tib si scaffolding thiab kinase cov haujlwm tshwj xeeb.

Hom phiaj: RIP1